Intravenous administration of adipose-derived stromal cells does not ameliorate bleomycin-induced lung injury in rats

Masato Uji, Akira Nakada, Tatsuo Nakamura

Department of Bioartificial Organs, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.

DOI: 10.4236/ojrm.2013.22007                

Abstract

Background: Mesenchymal stromal cells (MSCs) have been studied intensively in regenerative medicine. Among MSCs, adipose tissue-derived stromal cells (ASCs) are relatively easy to obtain from a patient. Since ASCs are ideal candidates for use in the treatment of disease states including pulmonary fibrosis, we investigated whether intravenous injection of ASCs could exert a therapeutic effect against bleomycin-induced lung injury in rats. Methods: Rats were intratracheally administered bleomycin, and one week later ASCs were isolated and cultured. Two weeks after bleomycin treatment ASCs or PBS (phosphate-buffered saline) were injected to the rats. Three or six weeks after bleomycin instillation, the total cell counts and their profile in bronchoalveolar lavage fluid (BALF) were measured, and a histological evaluation was semi-quantitatively assessed for the injured lungs, followed by cell tracing. Results: The BALF cell counts and its profiles were not significantly different in the ASCs and PBS groups. Furthermore, ASC treatment led to no significant histological effect compared with the PBS treatment. Using a fluorescent cell tracer, it was noted that the ASCs homed to the injured lung areas, but some ASCs accumulated around scars, and scarcely migrated into the fibrotic areas. Conclusions: In the present study, the intravenous administration of ASCs could not reduce the severity of bleomycin-induced lung injury in a rat model. Although the ASC counts and passage numbers were suitable, the older age and fibrotic disease stage of the rats were likely responsible for the treatment failure.

Keywords

Adipose Tissue; Aged; Mesenchymal Stromal Cells; Migration; Pulmonary Fibrosis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Talmadge, E., King, J., Costabel, U., Cordier, J.-F., Do-Pico, G.A., Bois, R.M.D. and Lynch, D. (2000) American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). American Journal of Respiratory and Critical Care Medicine, 161, 646-664. doi:10.1164/ajrccm.161.2.ats3-00
[2]	Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J. and Brown, K.K. (2011) An official ATS/ERS/JRS/ ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine, 183, 788-824. doi:10.1164/rccm.2009-040GL
[3]	Selman, M. and Pardo, A. (2004) Idiopathic pulmonary fibrosis: Misunderstandings between epithelial cells and fibroblasts? Sarcoidosis, Vasculitis, and Diffuse Lung Diseases, 21, 165-172.
[4]	Selman, M., King, T.E. and Pardo, A. (2001) Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Annals of Internal Medicine, 134, 136-151.
[5]	Bouros, D. and Antoniou, K.M. (2005) Current and future therapeutic approaches in idiopathic pulmonary fibrosis. European Respiratory Journal, 26, 693-702. doi:10.1183/09031936.05.00145004
[6]	Anstrom, K.J., Kaner, R.J., Loyd, J.E., Roman, J., Brown, K.K. and Kaner, R.J. (2010) The IPFnet strategy: Creating a comprehensive approach in the treatment of idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 181, 527-528. doi:10.1164/rccm.200903-0483ED
[7]	Hare, J.M., Traverse, J.H., Henry, T.D., Dib, N., Strumpf, R.K. and Schulman, S.P. (2009) A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology, 54, 2277-2286. doi:10.1016/j.jacc.2009.06.055
[8]	Stripp, B.R. and Shapiro, S.D. (2006) Stem cells in lung disease, repair, and the potential for therapeutic interventions: State-of-the-art and future challenges. American Journal of Respiratory Cell and Molecular Biology, 34, 517-518. doi:10.1165/rcmb.F315
[9]	Prockop, D.J. (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276, 71-74. doi:10.1126/science.276.5309.71
[10]	Lee, S.H., Jang, A.S., Kim, Y.E., Cha, J.Y., Kim, T.H. and Jung, S. (2010) Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. Respiratory Research, 11, 16. doi:10.1186/1465-9921-11-16
[11]	Zhao, F., Zhang, Y.F., Liu, Y.G., Zhou, J.J., Li, Z.K. and Wu, C.G. (2008) Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplantation Proceedings, 40, 1700-1705. doi:10.1016/j.transproceed.2008.01.080
[12]	Ortiz, L.A., Gambelli, F., McBride, C., Gaupp, D., Bad-doo, M. and Kaminski, N. (2003) Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proceedings of the National Academy of Sciences of the United States of America, 100, 8407-8411. doi:10.1073/pnas.1432929100
[13]	Rojas, M., Xu, J., Woods, C.R., Mora, A.L., Spears, W. and Roman, J. (2005) Bone marrow-derived mesenchymal stem cells in repair of the injured lung. American Journal of Respiratory Cell and Molecular Biology, 33, 145-152. doi:10.1165/rcmb.2004-0330OC
[14]	Cao, Y., Sun, Z., Liao, L., Meng, Y., Han, Q. and Zhao, R.C. (2005) Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochemical and Biophysical Research Communications, 332, 370-379. doi:10.1016/j.bbrc.2005.04.135
[15]	Rehman, J., Traktuev, D., Li, J., Merfeld-Clauss, S., Temm-Grove, C.J. and Bovenkerk, J.E. (2004) Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation, 109, 1292-1298. doi:10.1161/01.CIR.0000121425.42966.F1
[16]	Nakagami, H., Maeda, K., Morishita, R., Iguchi, S., Nishikawa, T. and Takami, Y. (2005) Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 2542-2547. doi:10.1161/01.ATV.0000190701.92007.6d
[17]	Lossos, I.S., Izbicki, G., Or, R., Goldstein, R.H. and Breuer, R. (2000) The effect of suramin on bleomycin-induced lung injury. Life Sciences, 67, 2873-2881. doi:10.1016/S0024-3205(00)00865-1
[18]	Tholpady, S.S., Katz, A.J. and Ogle, R.C. (2003) Mesenchymal stem cells from rat visceral fat exhibit multipotential differentiation in vitro. Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, 272, 398-402. doi:10.1002/ar.a.10039
[19]	Yoshimura, K., Shigeura, T., Matsumoto, D., Sato, T., Takaki, Y. and Aiba-Kojima, E. (2006) Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. Journal of Cellular Physiology, 208, 64-76. doi:10.1002/jcp.20636
[20]	Kingham, P.J., Kalbermatten, D.F., Mahay, D., Armstrong, S.J., Wiberg, M. and Terenghi, G. (2007) Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. Experimental Neurology, 207, 267-274. doi:10.1016/j.expneurol.2007.06.029
[21]	Yoshimura, H., Muneta, T., Nimura, A., Yokoyama, A., Koga, H. and Sekiya, I. (2007) Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell and Tissue Research, 327, 449-462. doi:10.1007/s00441-006-0308-z
[22]	Lee, C.C., Ye, F. and Tarantal, A.F. (2006) Comparison of growth and differentiation of fetal and adult rhesus monkey mesenchymal stem cells. Stem Cells and Development, 15, 209-220. doi:10.1089/scd.2006.15.209
[23]	Mareschi, K., Ferrero, I., Rustichelli, D., Aschero, S., Gammaitoni, L. and Aglietta, M. (2006) Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. Journal of Cellular Biochemistry, 97, 744-754. doi:10.1002/jcb.20681
[24]	Yue, B., Lu, B., Dai, K.R., Zhang, X.L., Yu, C.F. and Lou, J.R. (2005) BMP2 gene therapy on the repair of bone defects of aged rats. Calcified Tissue International, 77, 395-403. doi:10.1007/s00223-005-0180-y
[25]	Zhou, S., Greenberger, J.S., Epperly, M.W., Goff, J.P., Adler, C. and Leboff, M.S. (2008) Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell, 7, 335-343. doi:10.1111/j.1474-9726.2008.00377.x
[26]	Alt, E.U., Senst, C., Murthy, S.N., Slakey, D.P., Dupin, C.L. and Chaffin, A.E. (2012) Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Research, 8, 215-225. doi:10.1016/j.scr.2011.11.002
[27]	Crisostomo, P.R., Wang, M., Herring, C.M., Markel, T.A., Meldrum, K.K. and Lillemoe, K.D. (2007) Gender differences in injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 expression: Role of the 55 kDa TNF receptor (TNFR1). Journal of Molecular and Cellular Cardiology, 42, 142-149. doi:10.1016/j.yjmcc.2006.09.016
[28]	Hong, L., Sultana, H., Paulius, K. and Zhang, G. (2009) Steroid regulation of proliferation and osteogenic differentiation of bone marrow stromal cells: A gender difference. Journal of Steroid Biochemistry and Molecular Biology, 114, 180-185. doi:10.1016/j.jsbmb.2009.02.001
[29]	Fischer, U.M., Harting, M.T., Jimenez, F., Monzon-Posadas, W.O., Xue, H. and Savitz, S.I. (2009) Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells and Development, 18, 683-692. doi:10.1089/scd.2008.0253
[30]	Takasaki, Y., Watanabe, M., Yukawa, H., Sabarudin, A., Inagaki, K. and Kaji, N. (2011) Estimation of the distribution of intravenously injected adipose tissue-derived stem cells labeled with quantum dots in mice organs through the determination of their metallic components by ICPMS. Analytical Chemistry, 83, 8252-8258. doi:10.1021/ac202053y
[31]	Schrepfer, S., Deuse, T., Reichenspurner, H., Fischbein, M.P., Robbins, R.C. and Pelletier, M.P. (2007) Stem cell transplantation: The lung barrier. Transplantation Proceedings, 39, 573-576. doi:10.1016/j.transproceed.2006.12.019
[32]	Derubeis, A.R. and Cancedda, R. (2004) Bone marrow stromal cells (BMSCs) in bone engineering: Limitations and recent advances. Annals of Biomedical Engineering, 32, 160-165. doi:10.1023/B:ABME.0000007800.89194.95
[33]	Crisostomo, P.R., Wang, M., Wairiuko, G.M., Morrell, E.D., Terrell, A.M. and Seshadri, P. (2006) High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock, 26, 575-580. doi:10.1097/01.shk.0000235087.45798.93
[34]	Thrall, R.S., McCormick, J.R., Jack, R.M., McReynolds, R.A. and Ward, P.A. (1979) Bleomycin-induced pulmonary fibrosis in the rat: Inhibition by indomethacin. American Journal of Pathology, 95, 117-130.
[35]	Okada, S., Ishii, K., Yamane, J., Iwanami, A., Ikegami, T. and Katoh, H. (2005) In vivo imaging of engrafted neural stem cells: Its application in evaluating the optimal timing of transplantation for spinal cord injury. FASEB Journal, 19, 1839-1841.
[36]	Baek, S.J., Kang, S.K. and Ra, J.C. (2011) In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Experimental and Molecular Medicine, 43, 596-603. doi:10.3858/emm.2011.43.10.069